Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding distal interphalangeal joints). Subjects must have at least~1 psoriatic skin lesion. Exclusion Criteria:~• -Subject has known history of active tuberculosis.~* Subject has a planned surgical intervention between baseline and the week 52 evaluation.~* Subject has an active infection or history of infections.~* Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, diabetes, anemia) considered by the Investigator to be clinically significant and uncontrolled.~* Subject has any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.~Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)~• Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 210 mg brodalumab (Type: EXPERIMENTAL): Administered via subcutaneous injections.
- 140 mg brodalumab (Type: EXPERIMENTAL): Administered via subcutaneous injection.
- Placebo (Type: PLACEBO_COMPARATOR): Administered via subcutaneous injection until week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).